
Jacques Hugon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3280778/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Phosphorylation of eukaryotic initiation factor-2α (elF2α) is associated with neuronal degeneration in Alzheimer's disease. NeuroReport, 2002, 13, 2429-2432.	1.2	258
2	Involvement of doubleâ€stranded RNAâ€dependent protein kinase and phosphorylation of eukaryotic initiation factorâ€2α in neuronal degeneration. Journal of Neurochemistry, 2002, 83, 1215-1225.	3.9	153
3	Oxidative stress increases BACE1 protein levels through activation of the PKR-eIF2α pathway. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 885-896.	3.8	139
4	Long COVID: cognitive complaints (brain fog) and dysfunction of the cingulate cortex. Journal of Neurology, 2022, 269, 44-46.	3.6	127
5	Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study. Alzheimer's Research and Therapy, 2015, 7, 30.	6.2	101
6	Upstream Signaling Pathways Leading to the Activation of Double-stranded RNA-dependent Serine/Threonine Protein Kinase in β-Amyloid Peptide Neurotoxicity. Journal of Biological Chemistry, 2003, 278, 49819-49827.	3.4	87
7	Increased levels of cerebrospinal fluid JNK3 associated with amyloid pathology: links to cognitive decline. Journal of Psychiatry and Neuroscience, 2015, 40, 151-161.	2.4	75
8	Neuroinflammation and AÎ ² Accumulation Linked To Systemic Inflammation Are Decreased By Genetic PKR Down-Regulation. Scientific Reports, 2015, 5, 8489.	3.3	70
9	The oxindole/imidazole derivative C16 reduces in vivo brain PKR activation. FEBS Letters, 2007, 581, 4473-4478.	2.8	66
10	Impact of harmonization of collection tubes on Alzheimer's disease diagnosis. , 2014, 10, S390-S394.e2.		58
11	Modulation of Tau Phosphorylation by the Kinase PKR: Implications in Alzheimer's Disease. Brain Pathology, 2011, 21, 189-200.	4.1	55
12	Increased Cerebrospinal Fluid Levels of Double-Stranded RNA-Dependant Protein Kinase in Alzheimer's Disease. Biological Psychiatry, 2012, 71, 829-835.	1.3	52
13	Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease. Neurology, 2020, 95, e953-e961.	1.1	50
14	Cerebrospinal Fluid PKR Level Predicts Cognitive Decline in Alzheimer's Disease. PLoS ONE, 2013, 8, e53587.	2.5	46
15	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker–based case–control study. PLoS Medicine, 2020, 17, e1003289.	8.4	39
16	STAT3 inhibition protects against neuroinflammation and BACE1 upregulation induced by systemic inflammation. Immunology Letters, 2020, 228, 129-134.	2.5	38
17	PTK2B/Pyk2 overexpression improves a mouse model of Alzheimer's disease. Experimental Neurology, 2018, 307, 62-73.	4.1	36
18	Cognitive decline and brainstem hypometabolism in long COVID: A case series. Brain and Behavior, 2022, 12, e32513.	2.2	29

JACQUES HUGON

#	Article	IF	CITATIONS
19	PKR knockout in the 5xFAD model of Alzheimer's disease reveals beneficial effects on spatial memory and brain lesions. Aging Cell, 2019, 18, e12887.	6.7	28
20	PKR, a cognitive decline biomarker, can regulate translation <i>via</i> two consecutive molecular targets p53 and Redd1 in lymphocytes of AD patients. Journal of Cellular and Molecular Medicine, 2009, 13, 1823-1832.	3.6	27
21	A Novel ELISA for the Measurement of Cerebrospinal Fluid SNAP-25 in Patients with Alzheimer's Disease. Neuroscience, 2019, 420, 136-144.	2.3	25
22	Who Needs Cerebrospinal Biomarkers? A National Survey in Clinical Practice. Journal of Alzheimer's Disease, 2014, 40, 857-861.	2.6	22
23	Long-COVID: Cognitive deficits (brain fog) and brain lesions in non–hospitalized patients. Presse Medicale, 2022, 51, 104090.	1.9	22
24	Plasma amyloid beta predicts conversion to dementia in subjects with mild cognitive impairment: The BALTAZAR study. Alzheimer's and Dementia, 2022, 18, 2537-2550.	0.8	21
25	CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 88.	6.2	20
26	Emotional memory enhancement in respect of positive visual stimuli in Alzheimer's disease emerges after rich and deep encoding. Cortex, 2015, 65, 89-101.	2.4	19
27	CSF level of β-amyloid peptide predicts mortality in Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 29.	6.2	19
28	Biomarker counseling, disclosure of diagnosis and followâ€up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey. International Journal of Geriatric Psychiatry, 2021, 36, 324-333.	2.7	19
29	Biomarker profiles of Alzheimer's disease and dynamic of the association between cerebrospinal fluid levels of β-amyloid peptide and tau. PLoS ONE, 2019, 14, e0217026.	2.5	18
30	The PKR/P38/RIPK1 Signaling Pathway as a Therapeutic Target in Alzheimer's Disease. International Journal of Molecular Sciences, 2021, 22, 3136.	4.1	17
31	Time Orientation and 10 Years Risk ofÂDementia in Elderly Adults: TheÂThree-City Study. Journal of Alzheimer's Disease, 2016, 53, 1411-1418.	2.6	12
32	Dual Kinase Inhibition Affords Extended inÂvitro Neuroprotection in Amyloid-β Toxicity. Journal of Alzheimer's Disease, 2016, 54, 1659-1670.	2.6	11
33	Blood-Based Kinase Assessments in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2018, 10, 338.	3.4	11
34	Full-length and C-terminal neurogranin in Alzheimer's disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays. Alzheimer's Research and Therapy, 2020, 12, 168.	6.2	7
35	Rheumatoid arthritis and cognitive decline. Joint Bone Spine, 2022, 89, 105346.	1.6	7
36	Dose-dependent neuroprotective effect of the JNK inhibitor Brimapitide in 5xFAD transgenic mice. Brain Research, 2020, 1727, 146587.	2.2	6

JACQUES HUGON

#	Article	IF	CITATIONS
37	STAT3 inhibition reverses neuroinflammation and Al ² metabolism induced by systemic inflammation. Alzheimer's and Dementia, 2020, 16, e041019.	0.8	4
38	O2â€05â€01: CEREBROSPINAL FLUID SYNAPTIC VESICLE GLYCOPROTEIN 2A IN ALZHEIMER'S DISEASE. Alzheimer and Dementia, 2019, 15, P545.	.'S.8	2
39	[P1–240]: CLINICAL IMPACT OF CEREBROSPINAL FLUID BIOMARKERS IN MILD COGNITIVE IMPAIRMENT DIAGNOSIS. Alzheimer's and Dementia, 2017, 13, P336.	0.8	1
40	Could ryanodine receptor dysfunction be linked to PKR brain accumulations in Alzheimer's disease?. Medical Hypotheses, 2018, 113, 45.	1.5	1
41	P2-114: BRAIN AND CEREBROSPINAL FLUID C-JUN N TERMINAL KINASE 3 LEVELS IN ALZHEIMER'S DISEASE: LINKS TO COGNITIVE DECLINE. , 2014, 10, P512-P513.		Ο
42	P2-113: CSF AMYLOID-Î ² 42/40 RATIO IN CLINICAL SETTINGS: A MULTICENTRIC STUDY. , 2014, 10, P512-P512.		0
43	P4-313: Marked neuroprotection using dual kinase inhibition in AÎ ² neurotoxicity: A new bitherapy. , 2015, 11, P904-P904.		0
44	[P1–115]: THE KINASE PKR INTERFERES WITH BRAIN AMYLOID ACCUMULATION IN 5XFAD MICE. Alzheimer's and Dementia, 2017, 13, P284.	0.8	0
45	[P2–211]: AMYLOIDâ€Î²42 (Aβ42) DIFFERENTIALLY CORRELATES WITH CSF TOTAL AND HYPERPHOSPHORYLA TAU IN AN AMYLOIDâ€POSITIVE VERSUS AMYLOIDâ€NEGATIVE EARLY PRODROMAL AND ASYMPTOMATIC ATâ€R FOR AD POPULATION. Alzheimer's and Dementia, 2017, 13, P690.	TED ISK8	Ο
46	P1â€092: NEUROPROTECTIVE EFFECTS OF PKR KNOCKOUT IN 5XFAD ALZHEIMER MICE AND NEURONâ€MICROC COâ€CULTURES. Alzheimer's and Dementia, 2018, 14, P306.	LIA 0.8	0
47	CSF levels of the BACE1 substrate Neuregulin1 correlate with cognition and synaptic biomarkers in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e037097.	0.8	0
48	Title is missing!. , 2020, 17, e1003289.		0
49	Title is missing!. , 2020, 17, e1003289.		Ο
50	Title is missing!. , 2020, 17, e1003289.		0
51	Title is missing!. , 2020, 17, e1003289.		0
52	Title is missing!. , 2020, 17, e1003289.		0
53	Title is missing!. , 2020, 17, e1003289.		0
54	Title is missing!. , 2020, 17, e1003289.		0